Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions

2011 ◽  
Vol 26 (1) ◽  
Author(s):  
Alberto Lazarowski ◽  
Liliana Czornyj
2018 ◽  
Vol 17 (10) ◽  
pp. 728-735 ◽  
Author(s):  
Xiaolin Deng ◽  
Yangmei Xie ◽  
Yinghui Chen

Background & Objective: Epilepsy is a common and serious chronic neurological disorder that is mainly treated with antiepileptic drugs. Although current antiepileptic drugs used in clinical practice have advanced to the third generation, approximately one-third of patients are refractory to these treatments. More efficacious treatments for refractory epilepsy are therefore needed. A better understanding of the mechanism underlying refractory epilepsy is likely to facilitate the development of a more effective therapy. The abnormal expression and/or dysfunction of efflux transporters, particularly ABC transporters, might contribute to certain cases of refractory epilepsy. Inflammation in the brain has recently been shown to regulate the expression and/or function of ABC transporters in the cerebral vascular endothelial cells and glia of the blood-brain barrier by activating intracellular signalling pathways. Conclusion: Therefore, in this review, we will briefly summarize recent research advances regarding the possible role of neuroinflammation in regulating ABC transporter expression in epilepsy.


Antibiotics ◽  
2020 ◽  
Vol 9 (8) ◽  
pp. 468 ◽  
Author(s):  
Fátima Abreu-Salinas ◽  
Dafne Díaz-Jiménez ◽  
Isidro García-Meniño ◽  
Pilar Lumbreras ◽  
Ana María López-Beceiro ◽  
...  

The aim of this work was to assess the prevalence of extended spectrum-β-lactamase (ESBL)- and carbapenemase-producing Enterobacteriaceae in fecal samples recovered from rural and urban healthy dogs in Northwest Spain (Galicia) to identify potential high-risk clones and to molecularly characterize positive isolates regarding the genes coding for ESBL/pAmpC resistance and virulence. Thirty-five (19.6%) out of 179 dogs were positive for cephalosporin-resistant Enterobacteriaceae, including Escherichiacoli and Klebsiella pneumoniae (39 and three isolates, respectively). All the isolates were multidrug resistant, with high rates of resistance to different drugs, including ciprofloxacin (71.4%). A wide diversity of ESBL/pAmpC enzymes, as well as E. coli phylogroups (A, B1, C, D, E, F and clade I) were found. The eight isolates (20.5%) found to conform to the ExPEC status, belonged to clones O1:H45-clade I-ST770 (CH11-552), O18:H11-A-ST93-CC168 (CH11-neg), O23:H16-B1-ST453-CC86 (CH6-31), and O83:H42-F-ST1485-CC648 (CH231-58), with the latter also complying the uropathogenic (UPEC) status. The three K. pneumoniae recovered produced CTX-M-15 and belonged to the ST307, a clone previously reported in human clinical isolates. Our study highlights the potential role of both rural and urban dogs as a reservoir of high-risk Enterobacteriaceae clones, such as the CC648 of E. coli and antimicrobial resistance traits. Within a One-Health approach, their surveillance should be a priority in the fight against antimicrobial resistance.


2019 ◽  
Vol Volume 12 ◽  
pp. 2865-2874 ◽  
Author(s):  
Jialong Qi ◽  
Ruiyu Gao ◽  
Cunbao Liu ◽  
Bin Shan ◽  
Fulan Gao ◽  
...  

2008 ◽  
Vol 31 (3) ◽  
pp. 198-208 ◽  
Author(s):  
Marta Martins ◽  
Sujata G. Dastidar ◽  
Seamus Fanning ◽  
Jette E. Kristiansen ◽  
Joseph Molnar ◽  
...  

2021 ◽  
pp. 1-5
Author(s):  
Manaswini Dash ◽  
Subhashree Singh ◽  
Bhaskar Chandra Sahoo ◽  
Suprava Sahoo ◽  
Rajesh Kumar Sahoo ◽  
...  

Drugs ◽  
2017 ◽  
Vol 77 (9) ◽  
pp. 941-950 ◽  
Author(s):  
Grace Li ◽  
Joseph F. Standing ◽  
Julia Bielicki ◽  
William Hope ◽  
John van den Anker ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Zihe Yan ◽  
Junjun Yang ◽  
Renjing Hu ◽  
Xichi Hu ◽  
Kong Chen

Acinetobacter baumanniiis a significant cause of severe hospital-acquired infections with a recent rise in multidrug-resistant infections involving traumatic wounds of military personnel. The interleukin-17 (IL-17) pathway is essential for neutrophil recruitment in response to a variety of pathogens, while the control ofA. baumanniiinfection is known to be dependent on neutrophils. This suggests that IL-17 may play an important role inA. baumanniiinfection; however, this has yet to be studied. Here, we summarize the recent advances in understanding the host-pathogen interaction ofA. baumanniiand propose a potential role of the IL-17 pathway in generating a protective immune response.


2019 ◽  
Vol 63 (9) ◽  
Author(s):  
Tomefa E. Asempa ◽  
David P. Nicolau ◽  
Joseph L. Kuti

ABSTRACTRelebactam is a novel class A/C β-lactamase inhibitor that restores imipenemin vitroactivity against multidrug-resistant and carbapenem-nonsusceptiblePseudomonas aeruginosa. Time-kill analyses were performed to evaluate the potential role of imipenem-relebactam in combination with amikacin or colistin againstP. aeruginosa. Ten clinicalP. aeruginosaisolates (9 imipenem nonsusceptible) with imipenem-relebactam MICs ranging from 1/4 to 8/4 μg/ml were included. The isolates had varied susceptibilities to imipenem (1 to 32 μg/ml), amikacin (4 to 128 μg/ml), and colistin (0.5 to 1 μg/ml). Duplicate 24-h time-kill studies were conducted using the average steady-state concentrations (Cssavg) observed after the administration of imipenem-relebactam at 500 mg/250 mg every 6 hours (q6h) alone and in combination with theCssavgof 25 mg/kg of body weight/day amikacin and 360 mg/day colistin in humans. Imipenem-relebactam alone resulted in 24-h bacterial densities of −2.93 ± 0.38, −1.67 ± 0.29, +0.38 ± 0.96, and +0.15 ± 0.65 log10CFU/ml at imipenem-relebactam MICs of 1/4, 2/4, 4/4, and 8/4 μg/ml, respectively. No synergy was demonstrated against the single imipenem-susceptible isolate. Against the imipenem-nonsusceptible isolates (n = 9), imipenem-relebactam combined with amikacin resulted in synergy (−2.61 ± 1.50 log10CFU/ml) against all amikacin-susceptible isolates and in two of three amikacin-intermediate (i.e., MIC, 32 μg/ml) isolates (−2.06 ± 0.19 log10CFU/ml). Synergy with amikacin was not observed when the amikacin MIC was >32 μg/ml. Imipenem-relebactam combined with colistin demonstrated synergy in eight out of the nine imipenem-resistant isolates (−3.17 ± 1.00 log10CFU/ml). Against these 10 P. aeruginosaisolates, imipenem-relebactam combined with either amikacin or colistin resulted in synergistic activity against the majority of strains. Further studies evaluating combination therapy with imipenem-relebactam are warranted.


Epilepsia ◽  
2020 ◽  
Vol 61 (11) ◽  
pp. 2442-2451
Author(s):  
Gopikrishnan Unnikrishnan ◽  
Nikita Susan Jacob ◽  
Salma Salim ◽  
Manna Jose ◽  
Reshma A. Salini ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document